Boris Pasche, President and CEO of Karmanos Cancer Institute, shared on LinkedIn:
“Theranostics has transformed cancer treatment in the past decade.
Karmanos Cancer Institute has played a pivotal role in this innovative therapeutic approach, significantly contributing to the landmark Lutathera and Pluvicto registration studies.
With a comprehensive portfolio of advanced studies in Theranostics, Karmanos Cancer Institute provides the best treatment options available to patients. This cutting-edge approach is offered at three different locations in Michigan.
For more information about theranostic and radiopharmaceutical therapies at Karmanos, visit karmanos.org/theranostics.
To schedule a second opinion appointment, visit karmanos.org/secondopinion or call 1-800-KARMANOS.”
Other articles featuring Boris Pasche on OncoDaily.